Publisher
Springer Science and Business Media LLC
Subject
Cellular and Molecular Neuroscience,General Medicine
Reference26 articles.
1. ACMG Work Group on Management of Pompe Disease, Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, Case L, Crowley JF, Downs S, Howell RR, Kravitz RM, Mackey J, Marsden D, Martins AM, Millington DS, Nicolino M, O’Grady G, Patterson MC, Rapoport DM, Slonim A, Spencer CT, Tifft CJ, Watson MS (2006) Pompe disease diagnosis and management guideline. Genet Med Off J Am Coll Med Genet 8:267–288. https://doi.org/10.1097/01.gim.0000218152.87434.f3
2. Becker JA, Vlach J, Raben N, Nagaraju K, Adams EM, Hermans MM, Reuser AJ, Brooks SS, Tifft CJ, Hirschhorn R, Huie ML, Nicolino M, Plotz PH (1998) The African origin of the common mutation in African American patients with glycogen-storage disease type II. Am J Hum Genet 62:991–994. https://doi.org/10.1086/301788
3. Fereidoonnezhad M, Mostoufi A, Eskandari M, Zali S, Aliyan F (2018) Multitarget drug design, molecular docking and PLIF studies of novel Tacrine−Coumarin hybrids for the treatment of Alzheimer’s disease. Iran J Pharm Res IJPR 17:1217–1228
4. Gort L, Coll MJ, Chabás A (2007) Glycogen storage disease type II in Spanish patients: high frequency of c.1076-1G>C mutation. Mol Genet Metab 92:183–187. https://doi.org/10.1016/j.ymgme.2007.05.011
5. Hagemans MLC, Winkel LPF, Hop WCJ, Reuser AJJ, Van Doorn PA, Van der Ploeg AT (2005) Disease severity in children and adults with Pompe disease related to age and disease duration. Neurology 64:2139–2141. https://doi.org/10.1212/01.WNL.0000165979.46537.56